Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)
China
· Delayed Price · Currency is CNY 58.08
-0.78 (-1.33%)
Sep 6, 2024, 3:00 PM CST
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | -230.89 | -278.58 | -457.33 | -451 | -319.23 | -461.88 | Upgrade
|
| Depreciation & Amortization | 50.27 | 54.64 | 66.37 | 50.77 | 34.72 | 33 | Upgrade
|
| Other Amortization | 6.55 | 5.76 | 4.44 | 2.62 | 0.44 | 0.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.02 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.27 | 0.28 | 0.11 | 0.01 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -15.9 | -14.68 | -6.58 | -12.8 | -12.28 | -1.83 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.11 | 0.64 | 1.4 | 3.28 | - | - | Upgrade
|
| Other Operating Activities | 10.39 | 8.77 | -15.57 | -4.53 | 9.71 | 15.63 | Upgrade
|
| Change in Accounts Receivable | -47.42 | -38.35 | -17.41 | -84.19 | -20.87 | -11.01 | Upgrade
|
| Change in Inventory | -30.08 | -11.87 | -47.07 | -28.77 | -16.71 | -3.87 | Upgrade
|
| Change in Accounts Payable | 289.03 | 78.49 | 67.14 | 38.99 | -46.68 | 16.16 | Upgrade
|
| Change in Other Net Operating Assets | -16.09 | -34.11 | 37.07 | 34.62 | 31.12 | 237.45 | Upgrade
|
| Operating Cash Flow | 13.52 | -232.75 | -370.34 | -454.62 | -343.86 | -180.43 | Upgrade
|
| Capital Expenditures | -82.17 | -62.6 | -88.62 | -70.74 | -57.68 | -15.11 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0 | 0 | 0 | - | - | Upgrade
|
| Investment in Securities | 592.1 | 115 | -182.1 | 380.01 | -441.57 | 78.43 | Upgrade
|
| Other Investing Activities | 14.41 | 12.44 | 6.66 | 17.39 | - | - | Upgrade
|
| Investing Cash Flow | 524.34 | 64.84 | -264.06 | 326.66 | -499.25 | 63.33 | Upgrade
|
| Long-Term Debt Issued | - | 983.8 | 561 | 171.4 | 67.65 | 80 | Upgrade
|
| Long-Term Debt Repaid | - | -644.19 | -242.77 | -64.91 | -80 | -20 | Upgrade
|
| Net Debt Issued (Repaid) | 190.34 | 339.61 | 318.23 | 106.49 | -12.35 | 60 | Upgrade
|
| Issuance of Common Stock | 0.62 | 1,192 | - | - | 2,026 | 0.02 | Upgrade
|
| Common Dividends Paid | -24.3 | -21.17 | -11.22 | -4.14 | -1.11 | - | Upgrade
|
| Other Financing Activities | -0.19 | -1.45 | -24.23 | -8.36 | -113.1 | -5.7 | Upgrade
|
| Financing Cash Flow | 166.47 | 1,509 | 282.79 | 93.99 | 1,899 | 54.32 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.16 | 0.22 | 4.07 | -1.44 | -3.79 | 0.77 | Upgrade
|
| Net Cash Flow | 704.17 | 1,342 | -347.54 | -35.41 | 1,052 | -62.01 | Upgrade
|
| Free Cash Flow | -68.65 | -295.35 | -458.97 | -525.36 | -401.54 | -195.53 | Upgrade
|
| Free Cash Flow Margin | -16.86% | -76.43% | -151.82% | -275.98% | -1451.64% | - | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -1.16 | -1.92 | -2.19 | -1.71 | -1.09 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 1.16 | Upgrade
|
| Cash Income Tax Paid | 35.21 | 15.67 | -17.55 | -30.33 | 7.96 | 1.83 | Upgrade
|
| Levered Free Cash Flow | -317.67 | -325.09 | -297.1 | -353.47 | -238.38 | -27.62 | Upgrade
|
| Unlevered Free Cash Flow | -300.85 | -310.99 | -289.58 | -350.71 | -237.7 | -26.9 | Upgrade
|
| Change in Net Working Capital | 26.68 | 26.28 | -27.46 | 51.79 | 8.04 | -1.85 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.